At the American College of Cardiology 66th Scientific Session, Eric Peterson, MD, professor of medicine in the division of cardiology at Duke University School of Medicine, presented study findings that showed patients discontinued rivaroxaban less frequently than other anticoagulation agents. These results are important, he said, because regardless of what a clinician prescribes, “it’s the drugs that patients take that make the difference.”
At the American College of Cardiology 66th Scientific Session, Eric Peterson, MD, professor of medicine in the division of cardiology at Duke University School of Medicine and executive director of the Duke Clinical Research Institute, presented study findings that showed patients discontinued rivaroxaban less frequently than other anticoagulation agents. These results are important, he said, because regardless of what a clinician prescribes, “it’s the drugs that patients take that make the difference.”
Transcript (slightly modified)
Who was the study population for your research, and what were the findings?
We studied over 220,000 patients who had atrial fibrillation and looked at their various treatment patterns as well as their adherence to the medicines they were treated with. The major findings were that rivaroxaban, one of the novel oral agents, had higher rates of adherence, proportion of days covered greater than 80%, we found that over 80% of patients were able to take the medicines as prescribed. In contrast, some of the other agents, apixaban and dabigatran, were much lower at 70 to 75%, which was significantly less, and then even lower on those patients who were treated with warfarin.
Why did patients discontinue rivaroxaban less frequently than other anticoagulants?
I think it’s a combination of things, but in part that medicine once a day makes it easier for patients to take and it’s, in addition, well tolerated with regards to bleeding issues.
Why is it important to show that rivaroxaban is not just safe and effective, but also tolerable to patients?
At the end of the day, it’s the drugs that patients take that make the difference. We could order anything we can prescribe to patients, but if they don’t take it on a routine and consistent basis, then in fact the benefits that we expect will not be seen.
How do these findings contribute to the real-world evidence supporting rivaroxaban?
From clinical trials we get efficacy and safety, but from real-world data we get how patients actually take those medications and what it will mean to them long-term. In our study we showed that in fact rivaroxaban is better tolerated, is taken longer and more consistently by patients, which will result ultimately in hopefully better outcomes.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More